1195 related articles for article (PubMed ID: 33362722)
1. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
2. The expression profile of PD-L1 and CD8
Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX
J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Mei Y; Bi WL; Greenwald NF; Du Z; Agar NY; Kaiser UB; Woodmansee WW; Reardon DA; Freeman GJ; Fecci PE; Laws ER; Santagata S; Dunn GP; Dunn IF
Oncotarget; 2016 Nov; 7(47):76565-76576. PubMed ID: 27655724
[TBL] [Abstract][Full Text] [Related]
4. Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review.
Dai C; Liang S; Sun B; Li Y; Kang J
Front Oncol; 2021; 11():773905. PubMed ID: 34869016
[TBL] [Abstract][Full Text] [Related]
5. Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.
Lu JQ; Adam B; Jack AS; Lam A; Broad RW; Chik CL
Endocr Pathol; 2015 Sep; 26(3):263-72. PubMed ID: 26187094
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas.
Zhou W; Zhang C; Zhang D; Peng J; Ma S; Wang X; Guan X; Li P; Li D; Jia G; Jia W
J Neurooncol; 2020 Sep; 149(3):473-487. PubMed ID: 33034841
[TBL] [Abstract][Full Text] [Related]
7. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004
[TBL] [Abstract][Full Text] [Related]
8. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
[TBL] [Abstract][Full Text] [Related]
9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
10. Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.
Dai C; Sun B; Guan S; Wang W; Liu H; Li Y; Zhang J; Kang J
BMC Endocr Disord; 2021 Oct; 21(1):217. PubMed ID: 34715828
[TBL] [Abstract][Full Text] [Related]
11. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Ilie MD; Villa C; Cuny T; Cortet C; Assie G; Baussart B; Cancel M; Chanson P; Decoudier B; Deluche E; Di Stefano AL; Drui D; Gaillard S; Goichot B; Huillard O; Joncour A; Larrieu-Ciron D; Libe R; Nars G; Vasiljevic A; Raverot G
Eur J Endocrinol; 2022 Nov; 187(5):685-696. PubMed ID: 36111659
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
14. The Treatment of Refractory Pituitary Adenomas.
Dai C; Liu X; Ma W; Wang R
Front Endocrinol (Lausanne); 2019; 10():334. PubMed ID: 31191457
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and tumor-infiltrating CD8
Shi M; Song Y; Zhang Y; Li L; Yu J; Hou A; Han S
Front Endocrinol (Lausanne); 2023; 14():1151714. PubMed ID: 37424874
[TBL] [Abstract][Full Text] [Related]
16. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Kemeny HR; Elsamadicy AA; Farber SH; Champion CD; Lorrey SJ; Chongsathidkiet P; Woroniecka KI; Cui X; Shen SH; Rhodin KE; Tsvankin V; Everitt J; Sanchez-Perez L; Healy P; McLendon RE; Codd PJ; Dunn IF; Fecci PE
Clin Cancer Res; 2020 Mar; 26(5):1141-1151. PubMed ID: 31744830
[TBL] [Abstract][Full Text] [Related]
17. Refractory nonfunctioning pituitary adenomas.
Kolitz T; Greenman Y
Pituitary; 2023 Jun; 26(3):278-280. PubMed ID: 36786972
[TBL] [Abstract][Full Text] [Related]
18. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.
Lidhar K; Korbonits M; Jordan S; Khalimova Z; Kaltsas G; Lu X; Clayton RN; Jenkins PJ; Monson JP; Besser GM; Lowe DG; Grossman AB
J Clin Endocrinol Metab; 1999 Oct; 84(10):3823-30. PubMed ID: 10523037
[TBL] [Abstract][Full Text] [Related]
19. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma.
Yang Z; Tian X; Yao K; Yang Y; Zhang L; Liu N; Yan C; Qi X; Han S
Brain Sci; 2023 Jan; 13(2):. PubMed ID: 36831707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
